Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease.
Superoxide dismutases (SODs) are metalloenzymes that detoxify superoxide radicals, and occur in cytosolic (Cu,Zn-SOD) and mitochondrial (Mn-SOD) forms in multiple tissues, including brain. A neuroprotective effect against oxide stressor exposures may be provided by SOD, although excessive enzyme activity can produce cell injury by formation of hydroxyl radical from hydrogen peroxide. We measured Cu,Zn-SOD and Mn-SOD activities in peripheral lymphocytes of 43 newly diagnosed idiopathic Parkinson's disease (PD) cases and 62 age- and sex-matched controls free of neurodegenerative disorders. Significant excesses of both SOD forms were found among PD cases compared with controls; however, the excesses were found exclusively among PD patients treated with the monoamine oxidase inhibitor selegiline (L-deprenyl). Enzyme-linked immunosorbent assays (ELISAs) confirmed that the activity excesses were due to increased protein rather than more highly reactive enzymes in lymphocytes of PD cases. Our findings clearly indicate the importance of selegiline on measured Cu,Zn-SOD and Mn-SOD activity in peripheral lymphocytes. Characterizing a possible therapeutic value of SOD will require longitudinal assessments of SOD in relation to PD progression.
Kushleika
J
J
University of Washington, Department of Environmental Health, Seattle 98195-7234, USA.
Checkoway
H
H
Woods
J S
JS
Moon
J D
JD
Smith-Weller
T
T
Franklin
G M
GM
Swanson
P D
PD
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D003600:Cytosol / Q000201:enzymology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000201:enzymology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology*; D011506:Proteins / Q000378:metabolism; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use*; D013482:Superoxide Dismutase / Q000378:metabolism*
D000978:Antiparkinson Agents; D011506:Proteins; D012642:Selegiline; D013482:Superoxide Dismutase